# Insulin Glargine in Type 2 Diabetic Patients

> **NCT00347100** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 387 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin Glargine
- **DRUG:** Glyburide
- **DRUG:** Glyclazide
- **DRUG:** Glimiperide
- **DRUG:** Glipizide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT00347100
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-05
- **Final completion:** —
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2009-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347100, "Insulin Glargine in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00347100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*